Holen Sie sich die Stockscreener-App
37.57
8.36%
2.90
Handel nachbörslich:
37.30
-0.27
-0.72%
Schlusskurs vom Vortag:
$34.67
Offen:
$35.1
24-Stunden-Volumen:
27.98M
Relative Volume:
1.12
Marktkapitalisierung:
$8.70B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
71.96
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+14.89%
1M Leistung:
+35.34%
6M Leistung:
+15.71%
1J Leistung:
-21.66%
1-Tages-Spanne:
$34.75
$38.50
1-Wochen-Bereich:
$30.29
$38.50
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
37.57 | 8.02B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.95 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.40 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.44 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.45 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.15 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Establishes New $400 Million Receivables Facility - TipRanks
Hims & Hers Launches $400 Million Receivables Facility, Amends Revolver to Support Program - TradingView
Hims & Hers (HIMS) adds $400M receivables facility and amends credit deal - Stock Titan
HIMS Stock Surges as Canaccord Genuity Raises Price Target - GuruFocus
Hims & Hers Stock Surges as Analysts Lift Price Targets - Benzinga
Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review - TradingView
Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset - TechStock²
BofA raises Hims and Hers stock price target on FDA peptide review - Investing.com
Hims stock gains as FDA revives AdComs (HIMS:NYSE) - Seeking Alpha
HIMS Maintains by B of A Securities -- Price Target Raised to $3 - GuruFocus
HIMS Maintained by Canaccord Genuity -- Price Target Raised to $40 - GuruFocus
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Hims & Hers stock rises after Canaccord price target hike - Investing.com
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $29.27, Implies 16% Downside - TradingView
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Canaccord raises Hims and Hers stock price target on weight loss drugs - Investing.com Canada
HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’ - Stocktwits
Hims & Hers Health Inc (HIMS) Shares Surge 3.8% -- What GF Score of 81 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Lost Money on Hims & Hers Health, Inc. (HIMS)? Join Class Action Before August 25, 2025Contact Levi & Korsinsky - The National Law Review
Join Class Action to Recover Losses from Hims & Hers Health, Inc - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Hims & Hers - The National Law Review
Hims & Hers Health Stock (HIMS) Opinions on Business Reacceleration and Analyst Upgrades - Quiver Quantitative
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
Trading the Move, Not the Narrative: (HIMS) Edition - Stock Traders Daily
HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners - Stocktwits
OMCL or HIMS: Which Is the Better Value Stock Right Now? - Yahoo Finance UK
Hims & Hers Soars After Novo Nordisk Weight-Loss Nod - TipRanks
Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade) (NYSE:HIMS) - Seeking Alpha
Why is Hims & Hers Health stock up today? - Traders Union
Key facts: Hims sells GLP‑1s; 2.6M subs; Barclays $39, Leerink $25 - TradingView
Investor relations - HIMS Investor Relations
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Hims & Hers Health slips as investors continue to weigh margin pressure and recent financing - Quiver Quantitative
Hims’ obesity drug business may get boost as employers drop coverage - WTVB
Analysis-Hims’ obesity drug business may get boost as employers drop coverage - WHTC
$Hims & Hers Health (HIMS.US)$ - Moomoo
Barclays Raises Price Target On Hims & Hers Health (NYSE: HIMS) As Weight Loss Business Drives Momentum - foreignpolicyjournal.com
Hims & Hers Health Options Spot-On: On June 24th, 62,597 Contracts Were Traded, With 937.02K Open Interest - Moomoo
CVS expands direct-to-consumer GLP-1 weight-loss program - The Business Journals
Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock After Barclays’ Target Increase? - Insider Monkey
Form 4 Hims Hers Health Inc For: 23 June By Investing.com - Investing.com Nigeria
Hims & Hers CMO Patrick Carroll sells $830,410 in stock By Investing.com - Investing.com Canada
Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares By Investing.com - Investing.com Canada
Hims & Hers (NYSE: HIMS) CMO sells 23,726 shares, retains 181,861 - Stock Titan
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy - Yahoo Finance
2 Unpopular Stocks That Deserve a Second Chance and 1 We Question - The Globe and Mail
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.45%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):